Innodem Neurosciences reçoit un million de dollars de financement afin de donner une voix aux patients privés de la parole
19 févr. 2019 15h49 HE
|
Innodem Neurosciences
MONTRÉAL, 19 févr. 2019 (GLOBE NEWSWIRE) -- Innodem Neurosciences, jeune entreprise issue de l’Institut et hôpital neurologique de Montréal (Le Neuro) de l’Université McGill et membre de...
uniQure Announces Publications on AAV Gene Therapy Approach to Treating Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) in the Journal Molecular Therapy Nucleic Acids
15 févr. 2019 07h24 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Feb. 15, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
ALS related metabolic pathway discovered by Sheffield scientists using Biolog technology
13 févr. 2019 00h15 HE
|
Biolog, Inc.
SHEFFIELD, United Kingdom and HAYWARD, Calif., Feb. 13, 2019 (GLOBE NEWSWIRE) -- Researchers at the University of Sheffield have identified a new pathway that is disrupted in amyotrophic lateral...
Barrow Neurogolical Institute (Dignity Health) Collaborates With CloudMedx AI Platform to Create New Predictive Analytics Tools for the Management of Patients With Amyotrophic Lateral Sclerosis (ALS)
03 janv. 2019 16h07 HE
|
CloudMedx Inc.
PALO ALTO, Calif., Jan. 03, 2019 (GLOBE NEWSWIRE) -- CloudMedx, a healthcare AI company that provides real time and actionable insights to the healthcare industry, today announced its collaboration...
Biogen Exercises Option with Ionis to Develop and Commercialize Investigational Treatment BIIB067 for a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS) Based on Positive Phase 1 Data
06 déc. 2018 07h30 HE
|
Biogen Inc.; Ionis Pharmaceuticals, Inc.
Positive interim analysis demonstrated proof-of-biology and proof-of-concept for BIIB067Biogen plans to advance BIIB067 to a pivotal clinical studyBiogen paid Ionis Pharmaceuticals a $35 million...
Cytokinetics Completes Enrollment in FORTITUDE-ALS, Phase 2 Clinical Trial of Reldesemtiv in Patients With ALS
27 nov. 2018 07h30 HE
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the completion of patient enrollment in FORTITUDE-ALS (Functional Outcomes in...
Q Therapeutics Receives Orphan Drug Designation for Transverse Myelitis
26 sept. 2018 06h00 HE
|
Q Therapeutics, Inc.
FDA DESIGNATION WOULD PROVIDE 7 YEARS OF MARKET EXCLUSIVITY UPON MARKET APPROVAL OF Q-CELLS® SALT LAKE CITY, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Q Therapeutics, Inc., a developer of clinical-stage...
Orphazyme announces enrollment of first patient in Phase III clinical trial of arimoclomol for ALS
10 août 2018 12h19 HE
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No....
Voyager Therapeutics Announces Second Quarter 2018 Financial Results and Corporate Highlights
07 août 2018 16h07 HE
|
Voyager Therapeutics, Inc.
Clinical data updates and regulatory feedback for VY-AADC during the quarter support planned pivotal program for Parkinson’s disease Pipeline programs progressing with updated preclinical data from...
Voyager Therapeutics Announces New Data at the American Society of Gene and Cell Therapy 2018 Annual Meeting
17 mai 2018 18h15 HE
|
Voyager Therapeutics, Inc.
VY-SOD101 achieves meaningful suppression of disease-causing gene of ALS in large mammals after a one-time administration Results during the second half of 2018 from further delivery optimization...